Amgen studying genes to target pain conditions
For the next year, Amgen and Boston Children’s Hospital will use genetic analysis to study pain sensitivity. The biotech giant based in Thousand Oaks will work with patients who have abnormal pain conditions, and the hospital will validate genetic markers as potential targets for new therapies, the two announced in a press release on Oct. 16. “Traditional Read More →
Read More →
Amgen settles with AbbVie over Humira biosimilar litigation
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen lawsuit over cholesterol drug will get new trial
An Amgen lawsuit against a competing cholesterol drug will get a new trial but sales of the drug will be allowed in the U.S. until a decision is rendered. A federal court of appeals judge threw out a ban on the sale of Praluent, manufactured by New York-based Regeneron Pharmaceuticals and French biotech company Sanofi Read More →
Read More →Amgen settles with AbbVie over Humira biosimilar
Thousand Oaks biopharmaceutical giant Amgen announced Sept. 28 that it had reached a settlement with Chicago-based competitor AbbVie, which had sued to block Amgen’s Humira biosimilar Amjevita. The rheumatoid arthritis and inflammation treatment received U.S. Food and Drug Administration approval in September of 2016, but sales were blocked when AbbVie filed a patent infringement claim Read More →
Read More →Amgen reaffirms earnings outlook after hurricane hits Puerto Rico
After reviewing the impacts to its Puerto Rico manufacturing facility from Hurricane Maria, Thousand Oaks biotech giant Amgen reaffirmed its earnings outlook Sept. 25 and said that outreach to impacted staff was ongoing. The storm did not damage any product or in-process inventory at the plant, and the company said it did not expect any Read More →
Read More →Tri-county biotech companies targeting quality of life
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Study finds Amgen asthma drug is effective
An asthma drug being developed by Thousand Oaks-based Amgen and AstraZeneca showed significant yearly reduction for patients, according to a study published in the New England Journal of Medicine Sept. 6. Patients with severe, uncontrolled asthma using tezepelumab saw a drop in annual exacerbation compared with patients taking a placebo, Amgen said in a news Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
